Delivery Order SPE2DB22D3019-SPE2DB26FK2SG
Award Date 10/15/25
Potential Completion Date 10/16/25
Potential Value $6.1K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a $273,806 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes. The contract is a firm fixed price delivery order with no set-aside designation, executed on May 27, 2025, with an ultimate completion date of May 28, 2025. Performance will occur at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing the type...
- The Defense Logistics Agency awarded a $1,263.72 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B vaccine (20 mcg/0.5 mL syringe) on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $113,419 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 12, 2025, with completion targeted for August 13, 2025. This non-set-aside contract employs firm fixed pricing and represents a direct order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. HEPLISAV-B is a recombinant hepatitis B vaccine utilized by the Department of Defense for immunization programs...
- The Defense Logistics Agency awarded a $139,894.18 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $2,106.20. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 27, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...